Female Health (Nasdaq: FHCO) is expected to report Q2 earnings around April 19. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Female Health's revenues will grow 13.7% and EPS will increase 28.6%.

The average estimate for revenue is $8.9 million. On the bottom line, the average EPS estimate is $0.09.

Revenue details
 Last quarter, Female Health booked revenue of $9.9 million. GAAP reported sales were 15% higher than the prior-year quarter's $8.6 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, EPS came in at $0.12. GAAP EPS of $0.12 for Q1 were 33% higher than the prior-year quarter's $0.09 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 60.2%, 210 basis points better than the prior-year quarter. Operating margin was 36.3%, 410 basis points better than the prior-year quarter. Net margin was 35.7%, 490 basis points better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $38.9 million. The average EPS estimate is $0.54.

Investor sentiment
 The stock has a five-star rating (out of five) at Motley Fool CAPS, with 330 members out of 340 rating the stock outperform, and 10 members rating it underperform. Among 64 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 64 give Female Health a green thumbs-up, and give it a red thumbs-down.

Looking for alternatives to Female Health? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.